– 2026 Expansion of Production Facilities at the Yongin Plant
– 2026 Relocation of Headquarters to Gwacheon, Gyeonggi-do
– 2026 Lee Sun-jong Appointed as CEO
– 2025 FDA Clearance for BT-150B
– 2025 Patent Registration for BT-1000 ADHD Treatment Device
– 2025 Selected for the Regional Healthcare Innovation R&D Project
– 2025 New Patent Granted for BT-1000 ADHD Treatment Device
